

FEB 16 2005

Abbott Vascular Devices  
Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System

Special 510(k): Device Modification  
CONFIDENTIAL

## APPENDIX A. 510(k) SUMMARY

Sponsor/Submitter:	Abbott Laboratories Abbott Vascular Devices 400 Saginaw Drive Redwood City, CA 94063
Contact Person:	Ann E. Leonard Regulatory Affairs Coordinator Phone:(650) 474-3477 Fax:(650) 474-3041
Date of Submission:	January 17, 2005
Device Trade Name:	Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System
Device Common Name:	Biliary Stent and Delivery System
Device Classification:	Class II
Regulation Number:	21 CFR 876.5010
Classification Name:	Biliary Catheter and Accessories
Product Code:	78 FGE
Predicate Device:	Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System (K032929)
Intended Use:	The Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is intended for use in the palliation of malignant neoplasms in the biliary tree.
Device Description:	The Abbott Vascular Devices Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is comprised of a delivery system and a self-expanding stent. The delivery system is an over the wire (OTW) system designed to deliver the self-expanding stent to the biliary tree.
Summary of Substantial Equivalence:	The Xceed Nitinol Self-Expanding Transhepatic Biliary Stent System is substantially equivalent to the predicate device. Substantial equivalence was confirmed through non-clinical testing.



FEB 16 2005

Food and Drug Administration  
9200 Corporate Boulevard  
Rockville MD 20850

Ann E. Leonard, Ph.D.  
Regulatory Affairs Coordinator  
Abbott Vascular Devices  
400 Saginaw Drive  
REDWOOD CITY CA 94063

Re: K050103

Trade/Device Name: Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System  
Regulation Number: 21 CFR §876.5010  
Regulation Name: Biliary catheter and accessories  
Regulatory Class: II  
Product Code: 78 FGE  
Dated: January 17, 2005  
Received: January 18, 2005

Dear Dr. Leonard:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act). You may, therefore, market the device, subject to the general controls provisions of the Act and the limitations described below. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration.

The Office of Device Evaluation has determined that there is a reasonable likelihood that this device will be used for an intended use not identified in the proposed labeling and that such use could cause harm. Therefore, in accordance with Section 513(i)(1)(E) of the Act, the following limitation must appear in the Warnings section of the device's labeling:

The safety and effectiveness of this device for use in the vascular system have not been established.

Furthermore, the indication for biliary use must be prominently displayed in all labeling, including pouch, box, and carton labels, instructions for use, and other promotional materials, in close proximity to the trade name, of a similar point size, and in bold print.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

The FDA finding of substantial equivalence of your device to a legally marketed predicate device results in a classification for your device and permits your device to proceed to the market. This letter will allow you to begin marketing your device as described in your Section 510(k) premarket notification if the limitation statement described above is added to your labeling.

Please note that the above labeling limitations are required by Section 513(i)(1)(E) of the Act. Therefore, a new 510(k) is required before these limitations are modified in any way or removed from the device's labeling.

If you desire specific information about the application of other labeling requirements to your device (21 CFR Part 801), please contact the Office of Compliance at (301) 594-4616. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International, and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address <http://www.fda.gov/cdrh/dsma/dsmamain.html>.

Sincerely yours,

A handwritten signature in black ink, appearing to read "Donna-Bea Tillman", written in a cursive style.

Donna-Bea Tillman, Ph.D.  
Director  
Office of Device Evaluation  
Center for Devices and Radiological Health

Enclosure

510(k) Number: K050103

Device Name: Abbott Vascular Devices™ Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System

FDA's Statement of the Indications For Use for device:

The Abbott Vascular Devices Abbott Vascular Devices™ Xceed™ Nitinol Self-Expanding Transhepatic Biliary Stent System is intended for use in the palliation of malignant neoplasms in the biliary tree.

Prescription Use ✓  
(Per 21 CFR 801.109)

OR

Over-the-Counter Use \_\_\_\_\_

Nancy Brogan  
(Division Sign-Off)  
Division of Reproductive, Abdominal,  
and Radiological Devices  
510(k) Number K050103